Table 1.
Demographic data, vaccination status, comorbidities and clinical characteristics of Group A (un-hospitalized patients treated with nirmatrelvir/ritonavir) and Group B (untreated patients with oral antivirals).
| Study Group Group A (n = 200) |
Comparison Group Group B (n = 200) |
p Value | |
|---|---|---|---|
| Male gender, n (%) | 118 (59.0) | 121 (60.5) | 0.654 |
| Age Vaccination status |
75.24 ± 13.12 | 76.91 ± 14.02 | 0.970 |
| Single dose 2 doses (<6 months) 2 doses (>6 months) 1st booster dose 2nd booster dose Unvaccinated Previous SARS-CoV-2 infection |
5 (2.5) 7 (3.5) 65 (32.5) 90 (45.0) 20 (10.0) 13 (6.5) 17 (8.5) |
5 (2.5) 8 (4.0) 76 (38.0) 76 (38.0) 14 (7.0) 21 (10.5) 19 (9.5) |
0.547 0.447 0.867 0.997 1.000 0.657 0.657 |
| Comorbitidies | |||
| ΒΜΙ >30 | 59 (29.5) | 61 (30.5) | 0.758 |
| Hypertension | 129 (64.5) | 137 (68.5) | 0.987 |
| Diabetes mellitus | 74 (37) | 79 (39.5) | 0.765 |
| Heart Failure | 66 (33) | 67 (33.5) | 0.831 |
| Atrial Fibrilation | 29 (14.5) | 32 (16.0) | 0.867 |
| Ischemic heart disease | 31 (15.5) | 33 (16.5) | 0.826 |
| Neoplastic disease or hematologic malignancy | 44 (22) | 42 (21.0) | 0.631 |
| Respiratory problems | 18 (9) | 16 (8.0) | 0.727 |
| Immunosuppresion | 71 (35.5) | 69 (34.5) | 0.413 |
| Days of symptoms onset | 2 (1–4) | 7 (4–13) | <0.001 |
| Hospitalization | 3 (1.5) | 111 (55.5) | <0.001 |
| Days of hospitalization | 3 (2–5) | 10 (5–42) | <0.001 |
| Respiratory Failure | 0 (0.0) | 73 (36.5) | <0.001 |
| Intubation | 0 (0.0) | 6 (3.0) | 0.034 |
| Death | 0 (0.0) | 9 (4.5) | 0.052 |
| Time for recovery (days) | 5 (3–11) | 9 (5–18) | <0.001 |
| Rebound Infection Yes |
13 (6.5) | 16 (8.0) | 0.004 |